Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
8.28
0.00 (0.00%)
Jul 2, 2026, 4:00 PM EDT - Market closed
Emergent BioSolutions Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 160.3 | 205.4 | 99.5 | 111.7 | 642.6 | 576.1 |
Cash & Short-Term Investments | 160.3 | 205.4 | 99.5 | 111.7 | 642.6 | 576.1 |
Cash Growth | 7.51% | 106.43% | -10.92% | -82.62% | 11.54% | -7.27% |
Accounts Receivable | 121.6 | 84.2 | 154.5 | 191 | 159.2 | 278.9 |
Inventory | 327.6 | 343.4 | 311.7 | 328.9 | 350.7 | 344.5 |
Other Current Assets | 28.1 | 29.5 | 33 | 47.9 | 57.9 | 70.4 |
Total Current Assets | 637.6 | 662.5 | 598.7 | 679.5 | 1,210 | 1,270 |
Net Property, Plant & Equipment | 199.4 | 205.4 | 270.6 | 382.8 | 817.6 | 800.1 |
Other Intangible Assets | 470.4 | 436.5 | 501.5 | 566.6 | 728.8 | 604.6 |
Goodwill | - | - | - | - | 218.2 | 224.9 |
Other Long-Term Assets | 13 | 14.2 | 18.9 | 194.3 | 191.3 | 58.2 |
Total Assets | 1,320 | 1,319 | 1,390 | 1,823 | 3,166 | 2,958 |
Accounts Payable | 39.5 | 55.6 | 60.9 | 112.2 | 103.5 | 128.9 |
Accrued Expenses | 38.6 | 60.8 | 73.8 | 92.7 | 122.2 | 140.4 |
Short-Term Debt | - | - | - | 413.7 | 957.3 | 31.6 |
Current Portion of Long-Term Debt | - | - | - | 413.7 | 957.3 | 31.6 |
Unearned Revenue | 12.2 | 5 | - | - | - | - |
Other Current Liabilities | 58.4 | 10.8 | 27.7 | 32.7 | 45.9 | 73.1 |
Total Current Liabilities | 148.7 | 132.2 | 162.4 | 651.3 | 1,229 | 374 |
Long-Term Debt | 573.6 | 572.1 | 663.7 | 446.5 | 448.5 | 809.4 |
Other Long-Term Liabilities | 75 | 91.7 | 80.8 | 76.1 | 101.2 | 162.8 |
Total Long-Term Liabilities | 648.6 | 663.8 | 744.5 | 522.6 | 549.7 | 972.2 |
Total Liabilities | 797.3 | 796 | 906.9 | 1,174 | 1,779 | 1,346 |
Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
Treasury Stock | -261.6 | -252.6 | -227.7 | -227.7 | -227.7 | -152.2 |
Additional Paid-in Capital | 944.5 | 942.4 | 928 | 904.4 | 873.5 | 829.4 |
Accumulated Other Comprehensive Income | -6.9 | -7.5 | -5.2 | -5.7 | 3.1 | -16.1 |
Retained Earnings | -153 | -159.8 | -212.4 | -21.8 | 738.7 | 950.3 |
Shareholders' Equity | 523.1 | 522.6 | 482.8 | 649.3 | 1,388 | 1,612 |
Total Liabilities & Equity | 1,320 | 1,319 | 1,390 | 1,823 | 3,166 | 2,958 |
Total Debt | 573.6 | 572.1 | 663.7 | 1,274 | 2,363 | 872.6 |
Net Cash (Debt) | -413.3 | -366.7 | -564.2 | -1,162 | -1,721 | -296.5 |
Net Cash Per Share | -7.53 | -6.47 | -10.64 | -22.70 | -34.34 | -5.48 |
Book Value | 523.1 | 522.6 | 482.8 | 649.3 | 1,388 | 1,612 |
Book Value Per Share | 9.53 | 9.22 | 9.11 | 12.68 | 27.70 | 29.79 |
Tangible Book Value | 52.7 | 86.1 | -18.7 | 82.7 | 440.7 | 782 |
Tangible Book Value Per Share | 0.96 | 1.52 | -0.35 | 1.62 | 8.80 | 14.45 |